SCHEMBL5169216

SCHEMBL5169216

CN(C)C1CCN(Cc2ccc(-c3cnc(O)nc3)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.52
JAK2 O60674 1/20 0.47
MELK Q14680 3/20 0.47
LTA4H P09960 1/20 0.47
AXL P30530 3/20 0.46
MERTK Q12866 3/20 0.46
HRH3 Q9Y5N1 4/20 0.46
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
GRM2 Q14416 1/20 0.45
FLT3 P36888 1/20 0.44
TYRO3 Q06418 1/20 0.44
CHRM4 P08173 1/20 0.43
HSP90AA1 P07900 1/20 0.43
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
MAP4K4 O95819 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237162 0.95 HDAC1 (0.48) HDAC1JAK2MELKLTA4HAXL
SCHEMBL5166916 0.89 HDAC1 (0.48) HDAC1JAK2MELKLTA4HAXL
SCHEMBL5165601 0.85 HDAC1 (0.56) HDAC1JAK2MELKLTA4HAXL
SCHEMBL5168509 0.85 HDAC1 (0.46) HDAC1JAK2MELKLTA4HAXL
SCHEMBL5169162 0.85 HDAC1 (0.48) HDAC1JAK2MELKLTA4HAXL
SCHEMBL5164995 0.83 HDAC1 (0.53) HDAC1JAK2LTA4HAXLMERTK
SCHEMBL5188483 0.82 LSS (0.52) HDAC1JAK2LTA4HHRH3HRH2
SCHEMBL5191116 0.82 LSS (0.52) HDAC1JAK2LTA4HHRH3HRH2
SCHEMBL5165935 0.81 HDAC1 (0.63) HDAC1JAK2LTA4HHRH3CHRM4
SCHEMBL5166411 0.80 GRM2 (0.56) HDAC1JAK2LTA4HHRH3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771438-A1 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011042-A1 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060014733-A1 Histamine-3 agonists and antagonists PFIZER INC 2006-01-19 US claimed
US-20060014733-A1 Histamine-3 agonists and antagonists PFIZER INC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014733-A1 Histamine-3 agonists and antagonists HRH3, HRH4, HRH2 HDAC1 1532/4885JAK2 958/4885MELK 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.